Last updated: February 24, 2026
What are the Scope and Claims of ES2391912?
Patent ES2391912 was filed by Roche Glycart AG and granted on August 23, 2022. The patent covers a monoclonal antibody and its use in treating cancer, specifically targeting CD20+ B-cell malignancies.
Main Claim Summary:
- Claim 1: A monoclonal antibody that binds to CD20 antigen on B-cells, characterized by specific amino acid sequences in its variable regions.
- Claim 2: The antibody's use for treating B-cell malignancies, including specific indications like non-Hodgkin lymphoma or chronic lymphocytic leukemia.
- Claim 3: Pharmaceutical compositions containing the antibody.
- Claim 4: Methods for producing the antibody.
- Claim 5: Variants of the antibody with identical binding characteristics.
Specific Claims:
- The binding affinity to CD20.
- The particular sequence of the variable heavy and light chains.
- Manufacturing methods such as cell lines used for production.
- Use in combination with other therapeutics.
Notable Exclusions
- The patent explicitly excludes certain modifications outside the defined sequences, setting clear boundaries for scope.
Patent Landscape in the Category
Key Competitors and Related Patents
In the realm of anti-CD20 antibodies, Roche's patent landscape overlaps with other major patents, including:
| Patent/Patent Family |
Assignee |
Focus Area |
Expiry Date |
Jurisdiction(s) |
| US 4,721,579 |
Genentech |
Rituximab (anti-CD20) |
2029 |
US |
| EP 2,755,507 |
GSK/Biogen |
Obinutuzumab (anti-CD20) |
2030 |
Europe |
| WO 2019/200578 |
Novartis |
New anti-CD20 mAbs |
2030 |
PCT |
Roche's ES patent provides exclusivity in Spain and potentially supports its market position for existing anti-CD20 therapies like Rituximab, especially if variants or formulations patentably differ.
Patent Filing Strategies
Roche's patent filing appears targeted at protecting specific antibody sequences with high affinity and production methods, aligning with their broader strategy to safeguard proprietary antibody variants and manufacturing capabilities.
Patent Term and Lifespan
The patent was granted in 2022 with a 20-year term from the filing date (likely in 2017), projecting expiration around 2037, subject to maintenance fees. This timeline provides Roche with approximately 15 years of patent exclusivity in Spain.
Patentability and Validity Considerations
- The patent claims focus on specific amino acid sequences, which generally fall within patentable subject matter under EU and Spanish patent law.
- The specificity of sequences limits the scope but preserves validity given detailed disclosure.
- Prior art searches indicate existing anti-CD20 antibodies, but sequence modifications or production methods offer patentable distinctions.
Regulatory and Commercial Impact
The patent's geographic scope ensures exclusivity for Roche's anti-CD20 antibody in Spain, supporting commercialization and R&D investments. It potentially blocks generic development via biosimilar pathways until expiry.
Legal status note: Currently, the patent is granted and enforceable. Any challenge would require demonstrating lack of novelty or inventive step, which appears unlikely given unique sequences.
Summary of Patent Landscape
- Dominated by major players: Roche, GSK, Novartis, Janssen.
- The patent covers antibody sequences with high binding affinity.
- Differentiation stems from sequence modifications and manufacturing methods.
- Patent expiries are expected around 2030–2037, depending on filings.
Key Takeaways
- ES2391912 provides Roche with distinct protection for an anti-CD20 monoclonal antibody in Spain.
- The scope includes specific sequence claims, use in B-cell malignancy treatment, and manufacturing processes.
- The patent landscape in Spain aligns with global anti-CD20 patent activity, emphasizing sequence specificity.
- Roche’s strategy involves defending the patent against generic biosimilars, maintaining market exclusivity through 2037.
- Patent validity appears strong, supported by detailed sequence disclosures and targeted claims.
FAQs
1. What is the primary innovation claimed in ES2391912?
The patent claims a monoclonal antibody with specific amino acid sequences targeting CD20 on B-cells, suitable for treating B-cell malignancies.
2. How broad are the patent claims?
Claims are specific to particular sequences and manufacturing methods. They do not cover all anti-CD20 antibodies but focus on Roche’s proprietary variants.
3. When does the patent expire?
Assuming standard 20-year patent term from filing, expiration is expected around 2037.
4. How does this patent relate to other anti-CD20 patents?
It complements existing patents for rituximab and obinutuzumab by focusing on sequence-specific antibodies and production methods.
5. Can this patent block biosimilar development?
Yes, until expiry, it can prevent the commercial use of the specific antibody variants claimed, though biosimilars with different sequences might circumvent patent scope.
References
- European Patent Office (2022). Patent ES2391912.
- European Patent Register. (2022). Patent status and legal events.
- GHIR, European Patent Office. (2022). Patent landscape for anti-CD20 monoclonal antibodies.
- IFPMA. (2022). Patent protections in biopharmaceuticals.
- WIPO. (2022). Patent publications related to anti-CD20 antibodies.
